Safety, Tolerability and Pharmacokinetics of Half-Life Extended SARS-CoV-2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab/Cilgavimab) in Healthy Adults.
The Journal of infectious diseases（2023）
摘要
NCT04507256 (https://clinicaltrials.gov/ct2/show/NCT04507256).
更多查看译文
关键词
COVID-19,SARS-CoV-2,monoclonal antibody,pharmacokinetics,phase 1,safety,tolerability
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要